Abstract
Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Volume: 13 Issue: 1
Author(s): Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Massimo Iacoviello and Vincenzo Triggiani
Affiliation:
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Abstract: Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Export Options
About this article
Cite this article as:
Giagulli Vito Angelo, Guastamacchia Edoardo, Pergola Giovanni De, Iacoviello Massimo and Triggiani Vincenzo, Testosterone Deficiency in Male: A Risk Factor for Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010011
DOI https://dx.doi.org/10.2174/1871530311313010011 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome
Current Vascular Pharmacology Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus
Current Diabetes Reviews Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Use of Metformin and Survival of Diabetic Women with Breast Cancer
Current Drug Safety Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry Analogy of Cardiac and Renal Complications in Essential Hypertension and Aged SHR or L-NAME/SHR
Medicinal Chemistry Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Helicase Domain Containing Proteins in Human Disorders
Current Genomics In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Inhibition of Zinc Metallopeptidases in Cardiovascular Disease - From Unity to Trinity, or Duality?
Current Pharmaceutical Design Editorial (Thematic Issue: Mitochondrial and Metabolism: Novel Targets for Heart Failure)
Current Pharmaceutical Design Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Patient Education and Telemedicine in COPD
Current Respiratory Medicine Reviews Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery